We read with great interest the recent work of Pierre-Victor et al on prostate cancer
incidence and mortality in the Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial.
1
We previously reported, in 2017, on a similar cohort from this trial.
- Pierre-Victor D
- Parnes HL
- Andriole GL
- Pinsky PF
Prostate cancer incidence and mortality following a negative biopsy in a population
undergoing PSA screening.
Urology. 2021; (Published online June)https://doi.org/10.1016/j.urology.2021.05.060
2
We studied men in the screening arm who screened positive (via prostate-specific
antigen or digital rectal exam) during the first year of the trial, and whose linked
biopsy was negative. We found a similar mortality rate after a median follow-up of
12.9 years of 1.1% (vs 1.2% in the present study). The slightly divergent study design
and the longer survival follow-up as the data has matured (median 16.6 years in Pierre-Victor
et al) likely contribute to this slight difference. These results re-emphasize the
favorable prognostic significance of a negative prostate biopsy in the pre-MRI era.
These data remain highly relevant. They suggest that while magnetic resonance imaging
and targeted biopsy may be advantageous in terms of reducing repeat biopsies, given
the favorable prognosis among men with a prior negative biopsy in the pre-MRI era,
the window for a mortality benefit from these technologies appears remarkably narrow.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prostate cancer incidence and mortality following a negative biopsy in a population undergoing PSA screening.Urology. 2021; (Published online June)https://doi.org/10.1016/j.urology.2021.05.060
- Prognostic significance of a negative prostate biopsy: an analysis of subjects enrolled in a prostate cancer screening trial.J Urol. 2017; 197: 1014-1019https://doi.org/10.1016/j.juro.2016.11.002
Article info
Publication history
Published online: August 02, 2021
Accepted:
July 22,
2021
Received:
July 22,
2021
Footnotes
Funding support: The work presented here was not directly funded by an outside organization or sponsor. JES is supported by the The Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust, Vinney Scholars Award, and a Damon Runyon Cancer Research Foundation Physician Scientist Training Award. SV is supported by the Frederick J. and Theresa Dow Wallace Fund of the New York Community Trust and the Ferdinand C. Valentine Fellowship Award from the New York Academy of Medicine.
Identification
Copyright
© 2021 Elsevier Inc. All rights reserved.
